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Background: Leukemia incidence has increased in recent decades among European children,  suggesting 
that early-life environmental exposures play an important role in disease development.
oBjectives: We investigated the hypothesis that childhood susceptibility may increase as a result of 
in utero exposure to carcinogens and hormonally acting factors. Using cord blood samples from the 
NewGeneris cohort, we examined associations between a range of biomarkers of carcinogen exposure 
and hormonally acting factors with micronuclei (MN) frequency as a proxy measure of cancer risk. 
Associations with gene expression and genotype were also explored.
Methods: DNA and protein adducts, gene expression profiles, circulating hormonally acting factors, and 
GWAS (genome-wide association study) data were investigated in relation to genomic damage measured by 
MN frequency in lymphocytes from 623 newborns enrolled between 2006 and 2010 across Europe.
results: Malondialdehyde DNA adducts (M1dG) were associated with increased MN frequency in 
binucleated lymphocytes (MNBN), and exposure to androgenic, estrogenic, and dioxin-like compounds 
was associated with MN frequency in mononucleated lymphocytes (MNMONO), although no monotonic 
exposure–outcome relationship was observed. Lower frequencies of MNBN were associated with a 1-unit 
increase expression of PDCD11, LATS2, TRIM13, CD28, SMC1A, IL7R, and NIPBL genes. Gene expres-
sion was significantly higher in association with the highest versus lowest category of bulky and M1dG–DNA 
adducts for five and six genes, respectively. Gene expression levels were significantly lower for 11 genes in 
association with the highest versus lowest category of plasma AR CALUX® (chemically activated luciferase 
expression for androgens) (8 genes), ERα CALUX® (for estrogens) (2 genes), and DR CALUX® (for dioxins). 
Several SNPs (single-nucleotide polymorphisms) on chromosome 11 near FOLH1 significantly modified 
associations between androgen activity and MNBN frequency. Polymorphisms in EPHX1/2 and CYP2E1 
were associated with MNBN.
conclusion: We measured in utero exposure to selected environmental carcinogens and circulating hor-
monally acting factors and detected associations with MN frequency in newborns circulating T lympho-
cytes. The results highlight mechanisms that may contribute to carcinogen-induced leukemia and require 
further research.
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Introduction
Cancer incidence among European children, 
specifically leukemia, has steadily increased 
over the last three decades (Kaatsch 2010). 
In view of the relatively short latent period 
for leukemia and its very early onset in 
childhood, it has been suggested that fetal 
exposure to environmental carcinogens may 
increase susceptibility to this cancer (Wild 
and Kleinjans 2003).
The European Union (EU)–funded 
project Newborns and Genotoxic exposure 
risks (NewGeneris) was designed to evalu-
ate the hypothesis that maternal intake of 
dietary and other environmental carcinogens 
results in in utero exposure and early bio-
logical effects in the unborn child, possibly 
leading to increased risk of cancer in later 
childhood (Merlo et al. 2009). The primary 
aim of the present study was to investigate the 
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relationship between biomarkers of exposure 
to carcinogenic compounds and micro nuclei 
(MN) frequency in umbilical cord blood 
lympho cytes from the NewGeneris mother–
child birth cohort. The secondary aim was 
to ascertain whether  individual genotypes 
modify these relationships.
An array of exposure biomarkers quantify-
ing a range of potentially carcinogenic expo-
sures, many of dietary origin, were measured in 
fetal cord blood samples. DNA and hemoglo-
bin (Hb) adducts reflect biologically effective 
doses of exposure to genotoxic agents (Phillips 
2008). The DNA adducts selected for study 
were 3-(2´-deoxy-β-d-erythro-pentofuranosyl)-
pyrimido[1,2-α]purine-10(3H)-one (M1dG), 
O6-methyldeoxyguanosine (O6-MedG), and 
bulky DNA adducts. Hb adducts from acryl-
amide (AA), glycidamide (GA), and ethylene 
oxide (EtO) [for which data in this cohort have 
been published before (Pedersen et al. 2012)] 
were also evaluated, and three versions of the 
chemically activated luciferase gene expression 
(CALUX®) bioassay were used to assess expo-
sure to androgenic (AR), estrogenic (ERα), 
and dioxin-like (DR) compounds.
Facilitated by the development of micro-
array technologies, gene expression–based 
biomarkers have been developed and applied 
for human biomonitoring purposes (McHale 
et al. 2011; Rager et al. 2011; Ren et al. 2011; 
van Leeuwen et al. 2008). Gene expression 
profiling has the potential to identify new 
biomarkers of exposure that may simulta-
neously reflect the earliest biological events 
in disease pathogenesis. Here, we evaluated 
the expression of 36 genes that were asso-
ciated with biomarkers of carcinogen expo-
sure by quantitative real-time polymerase 
chain  reaction (qRT-PCR) (Hochstenbach 
et al. 2012).
MN frequency was assessed as the primary 
outcome. MN are a potential biomarker of 
cancer risk, because increased micronucle-
ated binucleated (MNBN) frequencies in 
T lymphocytes have been shown to be asso-
ciated with cancer risk in adults (Bonassi 
et al. 2007). MN are small extranuclear bod-
ies arising in dividing cells that are caused by 
chromosomal breakage and/or whole chro-
mosome loss (Fenech 2007; Kirsch-Volders 
et al. 2011). MNBN provide a measure of 
the lesions that have recently occurred 
in vivo, whereas micronucleated mono-
nucleated lymphocytes (MNMONO) give 
an estimation of the genome damage accu-
mulated over a long period in stem cells and 
circulating  lymphocytes (Kirsch-Volders and 
Fenech 2001).
Furthermore, we performed a genome-
wide association study (GWAS) to  investigate 
whether associations between exposure 
biomarkers and MN are modified by 
genetic variation.
Materials and Methods
Study population and sample collection. 
Pregnant women (n = 1,200) were enrolled 
between 2006 and 2010 in Heraklion, Crete, 
Greece; Barcelona and Sabadell, Spain; 
Bradford, England; Copenhagen, Denmark; 
and Oslo and Akerhus, Norway (Pedersen 
et al. 2012). The participation of mothers in 
the study was based on previously described 
eligibility criteria (Pedersen et al. 2012). 
Study protocols were approved by local 
 ethics committees, and informed consent 
was obtained from all participating mothers 
before sample collection.
Detailed information on personal charac-
teristics, including demographic, health, and 
lifestyle factors, was obtained using extensive 
questionnaires completed by mothers before 
or around the time of delivery. Information on 
dietary habits during pregnancy was obtained 
from country-specific food-frequency question-
naires (FFQs). Information on birth weight, 
gestational age, sex, and type of delivery was 
obtained from maternity records. Gestational 
age (completed weeks) was computed based 
on last menstrual period or  ultrasound-based 
estimated date of conception.
Blood samples were collected from 1,151 
mother–infant dyads following a common 
protocol as described previously (Merlo et al. 
2009). Umbilical cord blood samples were 
collected immediately after birth from the 
cord vein of newborns and locally processed. 
Samples were kept at –20°C or –80°C until 
shipment on dry ice to the study laboratories.
Biomarkers of exposure and early biologi-
cal effect. DR CALUX® bioassay. Dioxin-
like activity, expressed as aryl hydrocarbon 
receptor (AhR)–mediated activation of the 
extractable lipid fraction from plasma, was 
determined through the DR CALUX bio-
assay developed by BioDetection System 
(Murk et al. 1996). Blood was collected in 
heparinized tubes and plasma was isolated by 
centrifugation on the day of collection and 
frozen at –20oC. One to three milliliters of 
cord blood plasma was used for extraction of 
lipophilic compounds. The procedure for the 
DR CALUX® bioassay has been described in 
detail previously (Behnisch 2005). Additional 
information is provided in Supplemental 
Material (p. 3).
ERα  and AR CALUX® bioassays . 
Estrogenic and androgenic activity in cord-
blood plasma was determined using the ERα 
and AR CALUX® Bioassays. The ERα and 
AR CALUX® bioassays comprise human bone 
cell lines (U2OS), stably incorporating the 
firefly luciferase gene coupled to responsive 
elements (REs) as a reporter gene for the pres-
ence of (xeno-) estrogens (ERα CALUX®) and 
androgens (AR CALUX®) (Sonneveld et al. 
2005). Additional information is  provided in 
Supplemental Material (p. 4).
Hb adducts. Erythrocytes were isolated 
by centrifugation on the day of collection 
and stored at –20°C. AA–, GA–, and EtO–
Hb adducts were simultaneously determined 
by the adduct FIRE procedure using liquid 
chromatography tandem mass spectrometry 
with performance and validation standards as 
described in detail elsewhere (von Stedingk 
et al. 2010, 2011). In total, Hb adduct levels 
were measured in 1,151 cord blood samples.
DNA adducts. DNA was isolated with the 
Qiagen Midi Kit (no. 13343; Qiagen, Hilden, 
Germany) with some modifications of the 
manufacturer’s protocol, as reported previously 
(Kovács et al. 2011). Additional details are pro-
vided in Supplemental Material (pp. 4–8).
Immunoslot blot analysis of M1dG. 
M1dG was determined by an immunoslot 
blot method, using a murine M1dG mono-
clonal primary antibody (D10A1), pro-
vided by L. Marnett (Vanderbilt University, 
TN, USA), as described previously (Singh 
et al. 2001).
Immunochemical assays for analyses of 
O6-MedG and PAH–DNA adducts. These 
analyses were carried out using ultrasensi-
tive sandwich chemiluminescence immuno-
assays as previously described for O6-MedG 
(Georgiadis et al. 2011) and PAH (poly-
cyclic aromatic hydrocarbons)–DNA adducts 
(Georgiadis et al. 2012).
Postlabeling analysis of bulky DNA 
adducts. Bulky DNA adducts were detected 
with the nuclease P1 modification of the 
32P-postlabeling procedure as detailed else-
where (Kovács et al. 2011). Interlaboratory 
differences in levels were adjusted for, as 
described in Supplemental Material (p. 8).
Cytokinesis block micronucleus assay. 
The in vitro cytokinesis blocked MN assay 
was carried out according to the standard-
ized protocol developed for semiautomated 
image analysis (Decordier et al. 2009) and 
adapted for umbilical blood (Vande Loock 
et al. 2011). MN were scored in both MNBN 
and MNMONO T lymphocytes (Kirsch-
Volders and Fenech 2001). To harmonize 
slide preparation, the cohort cytologists were 
trained by I.D., K.V.L., and M.K.-V. (Vrije 
Universiteit Brussel; VUB). Slides were sent 
to VUB, where staining and MN analy-
sis occurred. Quality control after staining 
included visual selection of slides with good 
quality, using a light microscope and based 
on a good spreading, swelling, and amount 
of cells. The automated scoring procedure fol-
lowed by visual validation of selected micro-
nucleated cells was carried out by the same 
researcher, using the PathFinder™ platform 
installed by IMSTAR S.A. (Paris, France) 
at the VUB laboratory; this consisted of a 
PathFinder™ CELLSCAN™ capture station 
and two PathFinder™ MN analysis work-
stations. Reproducibility of the automated 
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image analysis combined with the visual vali-
dation step was investigated by assessing the 
intercapturing variability (Decordier et al. 
2009, 2011). At the end of the processing 
step, cells containing detected MN are pre-
sented one by one on the screen and con-
firmed or rejected by the scorer, according 
to the Human MicroNucleus project scor-
ing criteria (Fenech et al. 2003). According 
to guideline T487 of the Organisation for 
Economic Co-operation and Development 
(OECD), only subjects with at least 1,000 BN 
T lymphocytes counted were considered for 
statistical  analysis (OECD 2010).
Gene expression analysis. To preserve 
RNA for gene expression analysis, 0.4 mL 
of heparin-anticoagulated whole blood was 
mixed with 1.2 mL RNAlater (Ambion/
Applied Biosystems, Nieuwerkerk aan den 
Ijssel, the Netherlands) as soon as pos-
sible after blood collection. Samples were 
kept at –80°C until shipment on dry ice 
to the research laboratory at Maastricht 
University. Total RNA was isolated using the 
RiboPure-Blood system (Ambion) accord-
ing to the manufacturer’s instructions. RNA 
integrity was verified by gel electrophoresis 
(2100 BioAnalyzer; Agilent Technologies, 
Amstelveen, the Netherlands).
Fluidigm’s BioMark™ Dynamic Array 
(Fluidigm, Amsterdam, the Netherlands) 
technology was used for gene expression 
analyses by qRT-PCR, which was conducted 
by ServiceXS (Leiden, the Netherlands). 
Thirty-six genes were selected from a whole 
genome gene–environment interaction study 
on neonates (n = 84) from the Norwegian 
cohort (Hochstenbach et al. 2012). Selection 
was primarily based on correlations (r ≥ 0.75, 
≤ –0.75, p < 0.05) of gene expression with 
toxic dietary exposures (i.e., genotoxic or 
immunotoxic) estimated based on FFQs, 
CALUX assay–based evidence of exposure 
to estrogenic-, androgenic-, and dioxin-like 
compounds, Hb adduct levels, and MN 
frequencies. Only mechanistically relevant 
genes were selected, based on gene ontolo-
gies such as DNA repair, cell cycle, apoptosis, 
and cell proliferation. For each of the corre-
lations, mechanistically relevant genes were 
selected, resulting in 36 unique genes. Five 
reference genes were selected, based on low 
variance across all individuals. TaqMan gene 
expression assays (Applied Biosystems) were 
used (see Supplemental Material, Table S1), 
and qRT-PCR was conducted according to 
the manufacturer’s protocol. Each sample 
was analyzed in duplicate, and an average 
Ct (threshold cycle) value obtained. On all 
RT-PCR plates, a reference sample at vari-
ous dilutions was included for quality con-
trol assessment of interplate reproducibility. 
The raw Ct value upper cut-off was set to 26; 
genes exceeding this value were classified as 
unexpressed. For normalization, the average 
Ct of the five reference genes was subtracted 
from the Ct value of each gene.
Genome-wide association studies and 
 candidate genes analyses. We conducted 
a genome-wide scan of approximately 
300,000 tagging single nucleotide poly-
morphisms (SNPs) using the Illumina 
HumanCytoSNP-12 v1 (Illumina Inc., 
Hayward, CA, USA) according to the manu-
facturer’s protocols. Genotype calling was done 
using Illumina GenomeStudio 2010. Genomic 
DNA was isolated from 900 cord blood 
samples and was used to genotype each child. 
Quality control was performed on a per-sample 
and per-SNP basis. We excluded 33 duplicates, 
23 samples with a genotype call rate < 98.5%, 
and 14 twins, leaving 830 genotyped samples 
available for analysis. We used a general genetic 
model retaining the three distinct genotypes 
and without making any assumption about the 
direction of the SNP’s association in the het-
erozygote compared with the two homozygote 
classes. According to nonmutually exclusive 
SNP-based quality checks, 6,801 SNPs were 
excluded because of Hardy–Weinberg equilib-
rium violation (p < 10–6), 35,429 because they 
had a minor allele frequency (MAF < 1%), and 
7,338 because missing genotype was > 10%, 
resulting in 258,246 of 298,199 SNPs left for 
statistical analyses. A total of 435 newborns had 
both SNPs and MN results available, and they 
were used in GWAS statistical analyses.
In addition, SNPs present in metabolism 
and DNA repair genes were selected a priori 
by the consortium as candidate genes based 
on the available knowledge on functionali-
ties with respect to bioactivation (CYP1A1, 
CYP2E1, CYP2D6, EPHX1, and EPHX2) 
and detoxification (GSTM1) of DNA 
adduct–forming metabolites, base excision 
repair of oxidative adducts (OGG1), nucleo-
tide excision repair of bulky adducts (XRCC1, 
ERCC2/XPD, XPA, and XRCC3), repair of 
alkylated adducts (MGMT, ALKB, and MPG) 
and of thymine adducts (TDG), and with 
respect to folate metabolism, which is known 
to interfere with micronucleus formation 
(MTHFR, MTR, and MTRR).
Statistical analyses. Separate negative 
binomial fixed effects multivariable regres-
sion models were used to estimate the asso-
ciations of MN frequencies per 1,000 MNBN 
or MNMONO T lymphocytes (as depen-
dent variables) with AA–Hb, GA–Hb, and 
EtO–Hb adducts (picomoles per gram Hb, 
categorized into quintiles); M1dG–, PAH–, 
bulky, and O6-MedG–DNA adducts (per 108 
nucleotides, categorized into quartiles); and 
plasma levels of AR CALUX® (nanograms 
DHT AEQ/milliliters plasma), ERα CALUX® 
[nanograms ERα estradiol equivalents (EEQ)/
milliliters plasma], and DR CALUX® (pico-
grams TEQ/milliliters plasma) (categorized 
into quartiles); gene expression (normalized Ct 
value, continuous), GWAS data (i.e., all SNPs 
and a priori selected candidate genes), and the 
interactions between  biomarkers and SNPs.
Cohort (country), maternal age (continu-
ous), gestational age (continuous), prepreg-
nancy maternal body mass index (continuous), 
maternal smoking during pregnancy (any or 
none), environmental tobacco smoke (ETS) 
exposure during pregnancy (any or none), 
maternal ethnicity (Caucasian, others), and 
newborn sex and birth weight (continuous) 
were selected as potential confounders a priori 
and included in all models. Observations 
with missing covariates were excluded from 
the statistical analysis. We report the relative 
difference in the frequency of MN for each 
category of exposure relative to the lowest 
exposure category and the associations between 
1-unit increases in gene expression and MN 
frequency as the mean ratio (MR) and its 
95% CI. The likelihood ratio test was used as 
a global test of statistical significance over all 
categories of each exposure biomarker, SNPs 
allele variants, and the interactions between 
exposure biomarkers with gene expression and 
with SNPs. 
We estimated associations between the 
expression of each of the 36 genes evaluated 
and categorical exposure biomarkers using 
separate multivariable linear regression models 
adjusted for the covariates listed above. The 
F-test was used as a global test of statistical sig-
nificance over all categories of each exposure 
biomarker. For each exposure biomarker we 
report the differences in gene expression asso-
ciated with the highest versus lowest category 
of exposure biomarkers.
For gene expression and GWAS analyses, 
we adjusted the estimated p-values to account 
for multiple comparisons using standard 
methods (Benjamini and Hochberg 1995; 
Hochberg 1988; Holm 1979). This criterion 
was used to identify SNPs associated with 
MN as main predictors or as effect modifiers 
of the exposure biomarkers–MN and gene 
expression–MN associations. No adjustment 
was made for p-values estimated from the 
analyses of a priori–selected candidate genes. 
p-Values < 0.05 were considered statistically 
significant. All associations were examined 
in newborns with MN assay data available 
(n = 623) and with exposure biomarkers, gene 
expression, and GWAS data available. Sample 
sizes for individual association analyses varied 
as indicated in the results.
Manhattan plots for p-values along chro-
mosome and position were made by the genetic 
analysis package (gap) for CRAN R 2.11. 
Statistical analyses were carried out using Stata 
S.E. version 10.0 (StataCorp, College Station, 
TX, USA), R (http://cran.r-project.org), and 
Genedata Expressionist 7.0 (Genedata AG, 
Basel, Switzerland).
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Results
Levels of biomarkers of exposure (i.e., Hb 
and DNA adducts, and AR, ERα, and 
DR CALUX® activity) detected in newborns 
are reported in Table 1. The number of obser-
vations for each biomarker varied reflecting 
the variable amount of biological specimens 
collected from cord blood and the assays 
prioritization adopted (i.e., Hb adducts, 
DNA adducts, and CALUX® activity). The 
largest number of observations was avail-
able for AA–Hb adducts (n = 1,151) and 
the smallest for DR CALUX® (n = 725). For 
all biomarkers large variations were  present 
(e.g., AA–Hb adducts: median  = 14.4 
pmol/g Hb; range, 4.4–124.8; M1dG-DNA 
adducts: median = 9.9/108 nucleotides; range, 
0.5–324.7).
Descriptive statistics for MNBN and 
MNMONO T lymphocytes are shown in 
Table 2 by cohort and by sociodemographic, 
reproductive, and lifestyle factors. Again 
large interindividual variations were observed 
within and between cohorts, with the high-
est level of MN observed in Greece (MNBN 
mean = 1.79 ± 1.50 per 1,000 binucleated 
T lymphocytes) and the lowest in the United 
Kingdom (MNBN mean = 0.55 ± 0.74).
None of the global tests of associations 
across all categories of exposure were sta-
tistically significant, and there was no evi-
dence of monotonic dose–response trends 
with increasing levels of exposure for asso-
ciations of AA–, GA–, or EtO–Hb adducts 
(quintiles); PAH–, bulky–, or O6-MG–
DNA adducts (quartiles); or DR CALUX® 
plasma levels (quartiles) and frequencies of 
MNBN and MNMONO T lymphocytes 
(Table 3). A significant overall association 
was found between M1dG levels and the fre-
quency of MNBN lymphocytes, although 
associations relative to the lowest quartile 
of M1dG were positive for the second and 
third quartiles and negative for the highest 
quartile. ERα CALUX® plasma levels were 
significantly associated with the frequency 
of MNBN and MNMONO lymphocytes 
and AR CALUX® with the frequency of 
MNMONO lymphocytes. No monotonic 
exposure–outcome association was observed 
between ERα CALUX® or AR CALUX® and 
MN. For ERα CALUX® a significant nega-
tive association with MNBN was detected 
for the second quartile, followed by a weak 
nonsignificant positive association with the 
third and fourth quartiles while the associa-
tions with MNMONO were negative for the 
second and fourth quartiles. The strongest 
associations were detected for AR CALUX® 
and MNMONO T lymphocytes and were 
positive for the second and third quartiles and 
negative for the fourth quartile.
One-unit increases in the expression of 7 
of the 36 genes evaluated (PDCD11, LATS2, 
TRIM13, CD28, SMC1A, IL7R, and NIPBL) 
were associated with significantly lower 
MNBN frequencies, with MR ranging from 
0.81 (95% CI: 0.88, 0.96) for PDCD11 
to 0.64 (95% CI: 0.77, 0.97) for NIPBL 
(Figure 1A). The frequency of MNMONO 
was not significantly associated with expression 
of any of the genes tested (data not shown).
Table 1. Biomarkers of exposure measured in cord blood: descriptive statistics.
Biomarker of exposure (unit) n Mean ± SD Median IQR Min, Max
Acrylamide–Hb adducts (pmol/g Hb) 1,151 19.7 ± 16.5 14.4 10.8, 21.6 4.4, 124.8
Glycidamide–Hb adducts (pmol/g Hb) 1,150 13.7 ± 10.4 10.8 7.9, 15.7 2.0, 103.2
Ethylene oxide–Hb adducts (pmol/g Hb) 1,123 13.3 ± 13.8 9.4 6.6, 14.5 0.5, 174.2
M1dG (per 108 nucleotides) 892 53.1 ± 52.5 34.2 12.2, 82.7 0.5, 324.7
PAH–DNA adducts (per 108 nucleotides) 797 1.89 ± 2.09 1.39 0.58, 2.55 0.2, 28.3
Bulky DNA adducts (per 108 nucleotides) 635 11.8 ± 11.2 8.4 4.8, 15.3 0.6, 116.6
O6-MedG (per 108 nucleotides) 865 0.470 ± 0.501 0.287 0.075, 0.665 0.015, 3.033
AR CALUX® (ng DHT AEQ/mL plasma) 765 0.108 ± 0.098 0.099 0.059, 0.140 0.015, 2.142
ERα CALUX® (ng 17-β-estradiol EEQ/mL plasma) 765 22.1 ± 19.4 18.2 9.5, 28.5 0.01, 182.7
DR CALUX® (pg TEQ/mL plasma) 725 0.165 ± 0.137 0.130 0.055, 0.230 0.055, 1.043
Abbreviations: IQR, interquartile range; Max, maximum; Min, minimum. 
Table 2. MNBN and MNMONO T lymphocytes measured in cord blood (n = 623) by sociodemographic, 
reproductive, and lifestyle factors: descriptive statistics (mean ± SD).
Covariates n (%) MNBNa MNMONOa
Country
United Kingdom 143 (22.9) 0.55 ± 0.74 0.04 ± 0.14
Greece 232 (37.2) 1.79 ± 1.50 0.62 ± 0.71
Denmark 142 (22.7) 0.70 ± 0.58 0.17 ± 0.58
Spain 70 (11.2) 1.00 ± 1.00 0.20 ± 0.45
Norway 36 (5.77) 1.16 ± 0.92 0.11 ± 0.42
Maternal age (years)
≤ 27 170 (27.2) 1.31 ± 1.26 0.34 ± 0.59
28–30 131 (21.0) 1.11 ± 1.36 0.27 ± 0.53
31–32 96 (15.4) 1.11 ± 1.09 0.34 ± 0.61
33–35 109 (17.4) 1.17 ± 1.34 0.37 ± 0.73
≥ 36 112 (17.9) 0.85 ± 0.84 0.21 ± 0.55
Unknown 5 (0.80) 1.15 ± 1.43 0.20 ± 0.38
Prepregnancy BMI (kg/m3)
≤ 18.5 (underweight) 27 (4.33) 1.44 ± 1.19 0.39 ± 0.51
18.6–25.0 (normal) 316 (50.7) 1.20 ± 1.19 0.33 ± 0.65
25.1–30.0 (overweight) 112 (17.9) 1.27±1.36 0.25 ± 0.44
> 30 (obese) 78 (12.5) 1.07 ± 1.28 0.47 ± 0.78
Unknown 90 (14.4) 0.68 ± 0.92 0.13 ± 0.32
Birth weight (g)
Normal (≥ 2,500) 601 (96.4) 1.13 ± 1.22 0.31 ± 0.60
Low (< 2,500) 17 (2.72) 1.24 ± 0.88 0.37 ± 0.49
Unknown 5 (0.80) 1.32 ± 1.83 0.19 ± 0.38
Child sex
Male 315 (50.5) 1.10 ± 1.22 0.32 ± 0.63
Female 306 (49.1) 1.16 ± 1.21 0.30 ± 0.57
Unknown 2 (0.32) 0.37 ± 0.07 0.00 ± 0.00
Maternal ethnicity
Caucasian 522 (83.7) 1.21 ± 1.26 0.35 ± 0.64
Others 93 (14.9) 0.72 ± 0.86 0.08 ± 0.28
Unknown 8 (1.28) 0.44 ± 0.45 0.00 ± 0.00
Gestational age (weeks)
< 37 29 (4.65) 1.32 ± 1.62 0.30 ± 0.38
≥ 37 592 (95.0) 1.12 ± 1.19 0.31 ± 0.61
Unknown 2 (0.32) 1.22 ± 1.13 0.00 ± 0.00
Delivery
Vaginal 287 (46.0) 1.24 ± 1.26 0.35 ± 0.67
Caesarean 334 (53.6) 1.04 ± 1.17 0.27 ± 0.54
Unknown 2 (0.32) 0.48 ± 0.08 0.00 ± 0.00
Maternal smoking during pregnancy
None 470 (75.4) 1.06 ± 1.16 0.27 ± 0.58
Any 136 (21.8) 1.39 ± 1.37 0.47 ± 0.66
Unknown 17 (2.72) 0.89 ± 1.07 0.09 ± 0.25
ETS exposure during pregnancy
None 285 (45.7) 0.91 ± 0.91 0.18 ± 0.48
Any 231 (37.0) 1.26 ± 1.43 0.39 ± 0.68
Unknown 107 (17.1) 1.45 ± 1.32 0.46 ± 0.65
Abbreviations: BMI, body mass index; ETS, environmental tobacco smoke.
aNumber per 1,000 binucleated or mononucleated T lymphocytes.
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In models with gene expression levels as 
the dependent variable, expression was sig-
nificantly higher in association with the high-
est versus lowest category of bulky DNA 
adducts and of M1dG levels for five and six 
genes, respectively (Figure 1B). Conversely, 
expression levels were significantly lower 
for a total of 11 genes in association with 
the highest versus lowest category of plasma 
AR CALUX® (eight genes), ERα CALUX® 
(two genes), and DR CALUX® (seven genes) 
(Figure 1B). Associations with lower levels of 
exposure are not reported. Six of the seven 
genes whose expression was associated with 
significantly lower MNBN frequency (i.e., 
all except TRIM13; Figure 1A) were signifi-
cantly associated with the highest versus lowest 
category of at least one exposure biomarker 
(M1dG, DR CALUX®, ERα CALUX®, or 
AR CALUX®; Figure 1B). 
GWAS was carried out on 435 newborns 
with data available for both SNPs and micro-
nuclei. Confounding by population stratifica-
tion was assessed (see Supplemental Material, 
Figures S1 and S2) and confirmed that geno-
type variations occurred between population 
subgroups (i.e., maternal ethnicity and new-
borns’ country of birth), justifying the need 
for adjustment in statistical analyses. None 
of the GWAS SNPs were significant predic-
tors of MNBN frequencies (see Supplemental 
Material, Figure S3). Investigation of the 
exposure biomarkers–SNPs interactions on 
the occurrence of MNBN revealed a cluster 
of significant SNPs (on chromosome 11) for 
AR CALUX® modeled as a continuous vari-
able (see Supplemental Material, Figure S4). 
The four SNPs acting as effect modifiers of 
the relationship between AR CALUX® and the 
frequency of MNBN lymphocytes are given 
in Supplemental Material, Table S2. The asso-
ciation of these SNPs were reported per unit 
increase of plasma AR CALUX® and varied 
according to the allele variants. For each of the 
SNPs shown, there was a significant positive 
association between a 1-unit increase in plasma 
AR CALUX® and MNBN frequency among 
participants with one homozygous genotype, 
and a significant negative association with 
the alternate homozygous genotype (e.g., for 
rs7131537, MR = 2.54; 95% CI: 1.69, 3.75 
for CC and MR = 0.36; 95% CI: 0.21, 0.60 
for AA, with a null association among AC 
hetero zygotes compared with an overall 
 estimated association MR = 1.14; 95% CI: 
0.88, 1.47; data not shown).
Furthermore, 89 SNPs from the 18 a priori 
selected candidate genes were investigated for 
association with MN frequencies. SNPs in 
EPHX1, EPHX2, and CYP2E1 were signifi-
cantly associated (unadjusted overall p-value 
< 0.05) with the frequency of MNBN lym-
phocytes (Table 4). None of the candidate-
gene SNPs were significantly associated with 
Table 3. Relative difference in the frequency of MNBN and MNMONO T lymphocytes [mean ratio (MRa)] 
by category of exposure biomarkers estimated by negative binomial regression.
Exposure biomarker (unit) and category n (%)




Acrylamide–Hb adducts (pmol/g Hb) 0.468 0.873
≤ 10.2 95 (20.3) 1 1
10.3–13.9 93 (19.9) 1.06 (0.83, 1.35) 0.79 (0.48, 1.30)
14.0–18.4 94 (20.1) 1.00 (0.78, 1.28) 0.98 (0.62, 1.55)
18.5–27.8 93 (19.9) 0.97 (0.74, 1.27) 0.87 (0.53, 1.43)
> 27.8 92 (19.7) 1.24 (0.92, 1.68) 0.83 (0.46, 1.48)
Total 467 (100)
Glycidamide–Hb adducts (pmol/g Hb) 0.079 0.429
≤ 7.4 91 (19.4) 1 1
7.5–9.5 97 (20.7) 1.05 (0.83, 1.35) 1.17 (0.71, 1.94)
9.6–13.1 93 (19.9) 1.09 (0.85, 1.40) 1.10 (0.67, 1.82)
13.2–18.5 95 (20.3) 0.77 (0.58, 1.02) 0.74 (0.42, 1.31)
> 18.5 91 (19.4) 1.03 (0.76, 1.40) 0.79 (0.44, 1.41)
Total 467 (100)
Ethylene oxide–Hb adducts (pmol/g Hb) 0.336 0.676
≤ 6.3 89 (19.4) 1 1
6.4–8.5 94 (20.5) 1.22 (0.94, 1.58) 0.95 (0.55, 1.65)
8.6–11.5 93 (20.3) 1.22 (0.94, 1.59) 1.12 (0.64, 1.96)
11.6–16.8 91 (19.9) 1.08 (0.83, 1.41) 1.19 (0.70, 2.03)
> 16.8 90 (19.6) 1.01 (0.76, 1.33) 1.39 (0.81, 2.38)
Total 457 (100)
PAH–DNA adducts (per 108 nucleotides) 0.133 0.724
≤ 6.3 85 (24.5) 1 1
6.4–8.5 87 (25.1) 0.92 (0.71, 1.18) 0.97 (0.62, 1.53)
8.6–11.5 87 (25.1) 0.74 (0.56, 0.97) 1.20 (0.71, 2.01)
11.6–16.8 87 (25.1) 0.98 (0.76, 1.28) 0.89 (0.57, 1.41)
Total 346 (100)
Bulky DNA adducts (per 108 nucleotides) 0.096 0.757
≤ 4.60 77 (25.4) 1 1
4.70–7.90 73 (24.0) 1.20 (0.91, 1.59) 0.75 (0.37, 1.54)
8.00–14.78 77 (25.4) 0.90 (0.68, 1.20) 0.78 (0.41, 1.49)
> 14.78 76 (25.0) 0.85 (0.64, 1.14) 0.72 (0.40, 1.30)
Total 303 (100)
M1dG (per 108 nucleotides) 0.024 0.761
≤ 12.02 94 (24.6) 1 1
12.03–37.78 95 (24.9) 1.16 (0.91, 1.49) 0.99 (0.66, 1.49)
37.79–83.75 96 (25.1) 1.29 (0.99, 1.67) 1.18 (0.74, 1.88)
> 83.75 96 (25.1) 0.89 (0.69, 1.15) 0.90 (0.58, 1.41)
Total 381 (100)
O6-MedG (per 108 nucleotides) 0.539 0.111
≤ 0.076 133 (35.5) 1 1
0.077–0.389 79 (21.1) 0.99 (0.80, 1.23) 0.88 (0.60, 1.29)
0.390–0.810 81 (21.6) 1.16 (0.93, 1.45) 1.08 (0.73, 1.61)
> 0.810 81 (21.6) 1.06 (0.85, 1.34) 1.50 (1.00, 2.24)
Total 374 (100)
AR CALUX® (ng DHT AEQ/mL plasma) 0.103 0.002
≤ 0.086 65 (25.0) 1 1
0.087–0.118 63 (24.3) 1.46 (1.07, 2.00) 2.17 (0.99, 4.74)
0.119–0.151 67 (25.7) 1.37 (0.99, 1.92) 2.63 (1.19, 5.78)
> 0.151 65 (25.0) 1.38 (0.97, 1.96) 0.78 (0.28, 2.17)
Total 260 (100)
ERα CALUX® (ng 17-β-estradiol EEQ/mL plasma) 0.018 0.014
≤ 11.61 64 (24.8) 1 1
11.62–18.41 64 (24.8) 0.66 (0.46, 0.95) 0.54 (0.25, 1.20)
18.42–30.00 65 (25.1) 1.04 (0.77, 1.42) 1.41 (0.74, 2.70)
> 30.00 65 (25.1) 1.09 (0.78, 1.51) 0.57 (0.22, 1.51)
Total 258 (100)
DR CALUX® (pg TEQ/mL plasma) 0.182 0.355
≤ 0.055 73 (29.6) 1 1
0.056–0.180 49 (19.9) 0.79 (0.55, 1.12) 1.50 (0.81, 2.77)
0.181–0.280 63 (25.6) 1.14 (0.85, 1.54) 1.10 (0.57, 2.11)
> 0.281 61 (24.7) 1.12 (0.78, 1.61) 1.74 (0.83, 3.65)
Total 246 (100)
aMean ratio adjusted for country, maternal age, prepregnancy BMI, birth weight, sex, maternal ethnicity, gestational 
age, delivery, maternal smoking, and ETS. bNumber per 1,000 binucleated or mononucleated T lymphocytes. cLog likeli-
hood ratio test. 
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the frequency of MNMONO lymphocytes 
(data not shown).
Discussion
Here, we show that exposure biomarkers and 
T lymphocyte MN levels are measurable in 
cord blood, that large variations exist for these 
in the European newborn population, and 
also that some of the exposure biomarkers 
are associated with MN levels (as indepen-
dent variables) and with gene polymorphisms 
(when the biomarkers are modeled as depen-
dent variables). This suggests that the fetus 
may be exposed to carcinogenic chemicals 
in utero via the placenta, and that such expo-
sures may be sufficient to exert early biologi-
cal effects manifested as an increase in the 
frequency of MNBN, a marker that has been 
associated with cancer risk in adults (Bonassi 
et al. 2007). However, our findings should 
be interpreted with caution given that asso-
ciations did not show evidence of consistent 
dose–response relations with increasing levels 
of exposure.
M1dG is the major DNA adduct arising 
from malondialdehyde, a genotoxic by-prod-
uct of lipid peroxidation of polyunsaturated 
fatty acids with a high number of double 
bonds that also can be formed during food 
preparation (Jeong and Swenberg 2005). A 
significant overall association was detected 
between M1dG adduct levels and MNBN 
frequency, although the positive association 
was limited to the second and third quartiles, 
with the highest quartile of M1dG adducts 
being associated with the lowest MNBN fre-
quency when compared with the lowest quar-
tile. This association indicates recent exposure 
to malondialdehyde, because MNBN for-
mation reflects recent genetic damage that 
results in micronuclei formation when cell 
replication is induced in vitro. No associa-
tion was found between Hb adducts with 
MNMONO frequencies; however, fetal expo-
sure to compounds detected by ERα CALUX 
and AR CALUX induced significant increases 
of MNMONO, possibly reflecting genetic 
damage accumulated during fetal develop-
ment (Kirsch-Volders and Fenech 2001). The 
CALUX assays measure estrogenic, andro-
genic, or dioxin-like activities that could result 
from a variety of compounds or mixtures of 
compounds. Consequently, associations can-
not be attributed to specific exposures. Infant 
acute leukemia is a frequent childhood cancer, 
and maternal exposure to hormones during 
pregnancy has been reported as a potential 
risk in disease occurrence (Pombo-de-Oliveira 
and Koifman 2006). A recent review (Holland 
et al. 2011) on MN in neonates and children 
concluded that exposure to environmental 
pollutants and radiation leads to increased 
MN; however, no information was provided 
on possible associations with other biomarkers 
of exposure and/or early effect, as presented in 
the present study. 
The reduced number of samples avail-
able for the statistical analyses of the rela-
tionships between exposure biomarkers and 
MN levels is a limitation of the study and 
may have introduced false-negative findings. 
Conversely, some of the detected significant 
associations may have resulted from the mul-
tiple comparisons performed, increasing the 
chance of false-positive findings. In addition 
none of the observed associations followed a 
dose–response pattern.
We explored the expression of 36 genes 
by qRT-PCR as potential new biomarkers 
of toxic exposure. The expression of seven 
genes was negatively associated with MNBN 
(none with MNMONO), namely SMC1A, 
LATS2, TRIM13, PDCD11, CD28, IL7R, 
and NIPBL. The expression of these partic-
ular genes has previously been shown to be 
affected by one or more genotoxic carcino-
gens in experimental models (Mattingly et al. 
2003). However, because detailed exposure 
data were absent, we could not further sub-
stantiate the involvement of specific chemicals. 
Using the dedicated TRANSFAC® software 
(BIOBASE Biological Databases, Beverly, 
MA, USA; http://www.biobase-international.
com) for finding transcription factor expres-
sion in our transcriptomic data, we identified 
no transcription factor that could regulate all 
these genes. Given that MN are formed during 
metaphase/anaphase/telophase transition, it 
Figure 1. Associations between gene expression and MNBN T-lymphocyte frequency (A) and between 
exposure biomarkers and gene expression (B) adjusted for country, maternal age, prepregnancy BMI, 
birth weight, sex, maternal ethnicity, gestational age, delivery, maternal smoking, and ETS. Associations 
shown are those with multiple comparisons–adjusted p-values < 0.05. (A) Mean ratios (MR) are for 
associations between 1-unit increases in gene expression and MNBN based on 350 observations with 
complete data. (B) Differences in gene expression associated with the highest versus lowest category of 
exposure biomarkers are based on observations with complete data (bulky DNA adducts n = 398, M1dG 
DNA adducts n = 533, AR CALUX® n = 457; DR CALUX® n = 477; ER CALUX® n = 457). DR CALUX® cate-
gories were based on the following centiles: ≤ 0.13; 0.131–0.23; > 0.23 (pg TEQ/mL plasma) because 46% 
of the observations were tied (i.e., below the limit of detection of the assay). Boxed genes are significant 
predictors of MNBN and are significantly predicted by at least one exposure biomarker. Red rectangles 
are mean ratio point estimates of the associations between 1-unit increases in gene expression and 
MNBN (A), and regression coefficient point estimates of the differences in gene expression associated 
with the highest versus lowest category of exposure biomarkers (B). Whiskers are 95% CIs.
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was of interest that most of the genes identified 
are involved in progression through the cell 
cycle, cell division, spindle formation, or DNA 
damage responses. SMC1A encodes a protein 
that is part of the cohesin protein complex and 
is involved in sister chromatid cohesion dur-
ing the cell cycle (Bauerschmidt et al. 2011). 
The tumor suppressor gene LATS2 encodes 
a protein that interacts with centrosome pro-
teins and is required for correct spindle for-
mation (Abe et al. 2006). TRIM13 encodes 
a kinase involved in many different cellular 
processes including proliferation and apoptosis 
(Nakashima 2002). Furthermore, CD28 and 
PDCD11 are involved in apoptosis (Lacana 
and D’Adamio 1999; Walker et al. 1998). 
NIPBL is required for association of cohesin 
with chromosomes, for early processing of 
double-strand breaks and for the DNA dam-
age checkpoint (Oka et al. 2011). For IL7R, 
the biological relevance for its association with 
MNBN remains unclear.
The expression of six of the seven genes 
associated with MNBN was also associated 
with the highest versus lowest level of one 
or more exposure biomarkers (Figure 1). 
CD28, IL7R, and PDCD11A were associ-
ated with the mutagenic DNA adduct 
M1dG. CD28 and PDCD11 are mainly 
involved in processes linked to genotoxic 
stress, such as apoptosis and cell cycle (Lacana 
and D’Adamio 1999; Walker et al. 1998). 
LATS2 and SMC1A were associated with 
DR CALUX®, through which compounds 
that activate the transcription factor AhR, 
such as PCDDs (polychlorinated dibenzo-
dioxins), PCDFs (polychlorinated dibenzo-
furans), dioxin-like PCBs (polychlorinated 
biphenyls), and PAHs (Pedersen et al. 2010) 
are measured; many of the latter are geno-
toxic. Activation of the AhR participates in 
pathways such as cell cycle regulation, apop-
tosis and immune responses (Marlowe and 
Puga 2005). Although LATS2 and SMC1A 
are not known to be regulated by AhR, both 
genes are involved in certain subprocesses 
of the cell cycle. NIPBL was associated with 
AR CALUX®, which measures compounds 
with androgenic activity. Like AhR, AR is a 
transcription factor and regulates the expres-
sion of various genes involved in cell cycle 
control, apoptosis, cell growth, and differ-
entiation (Heisler et al. 1997). Although 
NIPBL is not known to be regulated by AR, 
it is linked to genotoxic stress related pro-
cesses and is involved in the cell cycle through 
its mediating function in sister chromatid 
 cohesion (Watrin et al. 2006).
In summary, associations between gene 
expression profiles and MN induction reflect 
the origin of MN: Many of the genes are 
associated with chromosome breakage or loss, 
and particularly interference with spindle and 
chromatid segregation. Their associations 
with exposure biomarkers support their rel-
evance in relation to genotoxic processes.
The analysis of genetic susceptibility 
was conducted using GWAS. A strong sig-
nal was observed on chromosome 11 for an 
interaction with AR CALUX® on MNBN fre-
quency (see Supplemental Material, Table S2, 
Figure S4). The gene closest to this hotspot is 
FOLH1 (folate hydrolase 1) and could thus 
be the genetic factor that affects this relation-
ship. Several pseudogenes were closer, but were 
excluded because their function is unclear. 
FOLH1, also known as PMSA (prostate- 
specific membrane antigen), is overexpressed in 
prostate cancer and is negatively regulated by 
androgen (Ghosh et al. 2005). Furthermore, 
a polymorphism in FOLH1 associated with 
lower levels of serum folate and hyperhomo-
cysteinemia has been described (Devlin et al. 
2000). Low folate is recognized as a risk factor 
for chromosome instability (Ames 2001) and 
MN induction (Fenech and Crott 2002). An 
interaction between androgen exposure and a 
polymorphism that modulates FOLH1 expres-
sion might affect folate levels and thereby 
modify MNBN frequencies.
GWAS was carried out on 435 newborns 
with data available for both SNPs and micro-
nuclei. The relatively small sample size is a 
limitation of the GWAS analysis and is likely 
to have introduced a risk of false-negative 
findings due to reduced statistical power to 
detect the studied associations. To reduce 
false-positive findings, we accounted for 
multiple comparisons in our primary GWAS 
analysis, although candidate gene analyses 
were not adjusted for multiple comparisons. 
We identified significant associations between 
a priori–selected SNPs in EPHX1, EPHX2, 
and CYP2E1 and the frequency of MNBN 
lymphocytes (Table 4). These SNPs do not 
affect the protein code, but might be in link-
age disequilibrium with causative variants. 
However, noncausal associations cannot be 
ruled out, and further clarification is required 
given inconsistent associations reported 
between these genes and MN in the literature 
(Dhillon et al. 2011).
In this study, samples from almost 1,200 
newborns were collected. Because of limited 
sample volumes, the number of biomarker 
measurements varied from 1,151 for the 
AA–Hb adduct to 623 for MNBN, and 435 
newborns had data available for both SNPs 
and micronuclei. For some analyses data were 
available for a limited number of observations: 
between 434 and 424 subjects for the asso-
ciations between MNBN and candidate SNPs, 
and < 220 subjects for the interactions SNPs–
exposure biomarkers on MNBN frequency. 
Although we were able to conduct association 
studies between individual exposure markers 
with MNBN, this seriously limited our ability 
to investigate the interaction between multiple 
exposure biomarkers and MNBN.
Conclusions
We demonstrated that gene expression, lym-
phocyte MN levels, and a variety of biomark-
ers of environmental (geno)toxic exposure can 
be measured in newborn cord blood samples, 
and that there is interindividual variation in 
these markers in the European population. 
Associations of exposure biomarkers and 
genes (at the level of both gene expression 
and genotype) with MN frequencies may help 
Table 4. Relationships between the available SNPs for the a priori–selected EPHX and CYP2E1 genes and 
frequency of MNBN T lymphocytes in newborns.
SNP Gene n
MNBNa  
(mean ± SE) MR (95 CI%)b p-Valuec
Rs1051741 EPHX1 424 0.011
GG 330 1.20 ± 0.07 1
AG 85 1.12 ± 0.11 1.04 (0.85, 1.27)
AA 9 0.32 ± 0.15 0.35 (0.17, 0.71)
Rs4149244 EPHX2 434 0.032
GG 377 1.17 ± 0.06 1
AG 50 1.04 ± 0.16 0.85 (0.66, 1.08)
AA 7 1.86 ± 0.48 1.89 (1.05, 3.39)
Rs2480258/Rs915906 CYP2E1 347 0.040
Other 331 1.03 ± 0.06 1
AA/GG 16 1.14 ± 0.33 1.53 (1.02, 2.28)
Rs2480258 CYP2E1 347 0.268
GG 203 1.02 ± 0.08 1
AG 119 1.05 ± 0.10 1.02 (0.86, 1.22)
AA 25 1.08 ± 0.25 1.38 (0.96, 1.98)
Rs915906 CYP2E1 347 0.265
AA 228 1.04 ± 0.08 1
AG 102 1.01 ± 0.10 1.07 (0.88, 1.29)
GG 17 1.09 ± 0.32 1.50 (0.99, 2.24)
Analyses carried out on 18 candidate genes with 89 SNPs available on the array. Only statistically significant relation-
ships are reported. For the Rs2480258/Rs915906 SNPs, relationships estimated for the single SNPs are shown.
aMean ± SE per 1,000 binucleated T lymphocytes. bMean ratio adjusted for country, maternal age, prepregnancy BMI, 
birth weight, sex, maternal ethnicity, gestational age, delivery, maternal smoking, and ETS. cLog-likelihood ratio test, 
unadjusted for multiple comparisons.
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generate new hypotheses about mechanisms 
of carcinogen-induced leukemia. The associa-
tions that we report must be interpreted with 
caution because we did not measure specific 
exposures, we did not observe monotonic 
dose–response relations, and we cannot rule 
out noncausal associations.
Nevertheless, our results suggest that inter-
nal exposure of the fetus to toxic chemicals 
occurs during apparently normal pregnancies, 
that such exposures may increase the frequency 
of MN formation [which, although of uncer-
tain relevance in newborns (Holland et al. 
2011) has been associated with cancer risk in 
adults (Bonassi et al. 2007)], and that some 
children may be more susceptible to genotoxic 
effects of in utero exposures than others.
Ultimately, information on the effects and 
sources of in utero genotoxic exposures could 
be used by regulators and industry to develop 
policy measures and strategies to reduce such 
exposures in order to improve children’s health 
and reduce the incidence of childhood cancer.
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